Hepatitis, rhabdomyolysis and multi-organ failure resulting from statin use

Rajaram, Muthuram

doi:10.1136/bcr.07.2008.0412

Cited by 2 publications

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 2009, Muthuram et al [10] reported the case of a 77-year-old man diagnosed with aortic stenosis, whose atorvastatin dose was increased from 40 mg to 80 mg 6 months before presentation. He presented with acute hepatitis, rhabdomyolysis, and acute renal failure.…”

Section: Discussionmentioning

confidence: 99%

Statin-Induced Rhabdomyolysis, Acute Kidney Injury, and Hepatitis Leading to Death

2019

View full text Add to dashboard Cite

Patient: Male, 67 Final Diagnosis: Statin-induced rhabdomyolysis and hepatitis Symptoms: Dark urine • muscle pain • muscle weakness • pale stool • yellowish skin discoloration Medication: Atorvastatin Clinical Procedure: Dialysis Specialty: General and Internal Medicine Objective: Unusual or unexpected effect of treatment Background: Statins are effective in reducing cardiovascular morbidity and mortality, and are generally safe, but can rarely result in devastating adverse effects. With the increasing indications and prescriptions of statins, rare adverse effects are more likely to be seen and reported. Unfortunately, there are no accurate predictive tools to estimate the risk of developing these adverse effects. Post-marketing surveillance helps in collecting data on adverse effects and assists in developing better prognostic tools that can help physicians make better therapeutic decisions. Case Report: A 67-year-old man was admitted to our hospital with generalized body aches, muscle weakness, jaundice, dark urine, and decreased urine output. He was started on atorvastatin 4 months prior to presentation after having an episode of myocardial infarction, and he was diagnosed as having statin-induced hepatitis, rhabdomyolysis, and acute kidney injury. A basic workup excluded other possible causes. The patient, unfortunately, died of unknown causes on day 6 after admission, and an autopsy was not performed. Conclusions: Statins are effective and safe but can result in rare and dangerous adverse effects. Physicians should counsel their patients on proper identification and timely reporting of such adverse effects. Physicians also should be encouraged to report any adverse drug reactions and help in promoting post-marketing surveillance studies. The present case is an excellent example of the importance of these studies, especially for commonly-used drugs.

show abstract

Section: Discussionmentioning

confidence: 99%

Statin-Induced Rhabdomyolysis, Acute Kidney Injury, and Hepatitis Leading to Death

2019

View full text Add to dashboard Cite

show abstract

“…7 As shown in Table 1, there are 11 published cases of atorvastatin-induced rhabdomyolysis including our case report, with 7 cases occurring in patients who are 65 years or older and 3 cases occurring in patients who are 76 years and older. [12][13][14][15][16][17][18][19][20][21] In addition to age, several patients had other risk factors for rhabdomyolysis. For example, 2 patients had a history of chronic renal disease and 1 patient had a history of cirrhosis.…”

Section: Discussionmentioning

confidence: 99%

High-Intensity Atorvastatin-Induced Rhabdomyolysis in an Elderly Patient With NSTEMI: A Case Report and Review of the Literature

Huynh

Lee

2016

Journal of Pharmacy Practice

View full text Add to dashboard Cite

A 91-year-old male was admitted to the hospital for worsening muscle weakness, muscle pain, and unexplained soreness for the past 10 days. Four months prior to his admission, the patient had experienced a myocardial infarction and was initiated on atorvastatin 80 mg daily. Although the provider had instructed the patient to decrease the atorvastatin dose to 40 mg daily 3 months prior to admission, the patient did not adhere to the lower dose regimen until 10 days prior to hospitalization. Upon admission, the patient presented with muscle weakness and pain, a serum creatinine phosphokinase of 18 723 U/L, and a serum creatinine of 1.6 mg/dL. The atorvastatin dose was held and the patient was treated with intravenous fluids. The 2013 American College of Cardiology and American Heart Association Blood Cholesterol Practice Guidelines recommend the use of moderate-intensity statins in patients older than 75 years to prevent myopathy. However, in clinical practice, aggressive statin therapy is often prescribed for significant coronary disease. Prescribing high-intensity statins for patients with advanced age, such as this case, may increase the risk of rhabdomyolysis and other complications. This case report suggests that providers should avoid or be cautious with initiating high-intensity atorvastatin in elderly patients over 75 years to minimize the risk of rhabdomyolysis.

show abstract

Hepatitis, rhabdomyolysis and multi-organ failure resulting from statin use

Cited by 2 publications

References 14 publications

Statin-Induced Rhabdomyolysis, Acute Kidney Injury, and Hepatitis Leading to Death

Statin-Induced Rhabdomyolysis, Acute Kidney Injury, and Hepatitis Leading to Death

High-Intensity Atorvastatin-Induced Rhabdomyolysis in an Elderly Patient With NSTEMI: A Case Report and Review of the Literature

Contact Info

Product

Resources

About